Abstract

The purpose of the Developmental Research Program of the MSKCC SPORE in Prostate Cancer is to support innovative translational research projects in prostate cancer. This program will allow us to respond quickly to new opportunities in translational research.
The specific aims of the DRP are:
Aim 1. To provide seed funding for innovative, investigator-initiated research in the etiology, prevention, diagnosis, and treatment of prostate cancer Aim 2. To fund research with exceptional potential to advance the translational research goals of the SPORE. This mechanism will allow the SPORE leadership to respond rapidly to new research opportunities.
Aim 3. To establish a mechanism for strategic interactions with other SPOREs and other major national and international research centers The Executive Committee will prioritize pilot projects for support based on novelty and programmatic need resulting from the Committee's review of work presented at our research meetings, including the Prostate Cancer Working Group (weekly), SPORE Scientific Seminar Series (monthly), Genitourinary Disease Management Team (monthly), Multi-institutional Prostate Cancer Program Retreat (annual), and the MSKCC Geoffrey Beene Cancer Research Center Retreats (annual). This ensures the steady infusion of new ideas and techniques into our SPORE in Prostate Cancer program. Preference will be given to projects that complement the long-term research goals of the SPORE and advance our translational research objectives. The Executive Committee can also solicit and fund experimental or clinical initiatives that address an urgent and specific need in the MSKCC SPORE in Prostate Cancer program or a unique research opportunity.

Public Health Relevance

As a public health concern, prostate cancer is the second deadliest cancer in men. The translational research projects in this program aim to use knowledge of animal and human prostate cancer biology to develop and test interventions related to the prevention, early detection, diagnosis, prognosis, and treatment of prostate cancer in men.

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
2P50CA092629-16
Application #
9148029
Study Section
Special Emphasis Panel (ZCA1)
Project Start
2001-09-14
Project End
2021-08-31
Budget Start
2016-09-01
Budget End
2017-08-31
Support Year
16
Fiscal Year
2016
Total Cost
Indirect Cost

  Institution

Name
Sloan-Kettering Institute for Cancer Research
Department
Type
DUNS #
064931884
City
New York
State
NY
Country
United States
Zip Code
10065

  Publications

Han, SoHyun; Stoyanova, Radka; Lee, Hansol et al. (2018) Automation of pattern recognition analysis of dynamic contrast-enhanced MRI data to characterize intratumoral vascular heterogeneity. Magn Reson Med 79:1736-1744
Vickers, Andrew J; Steineck, Gunnar (2018) Prognosis, Effect Modification, and Mediation. Eur Urol 74:243-245
Kinsella, Netty; Helleman, Jozien; Bruinsma, Sophie et al. (2018) Active surveillance for prostate cancer: a systematic review of contemporary worldwide practices. Transl Androl Urol 7:83-97
Hieronymus, Haley; Murali, Rajmohan; Tin, Amy et al. (2018) Tumor copy number alteration burden is a pan-cancer prognostic factor associated with recurrence and death. Elife 7:
Scher, Howard I; Graf, Ryon P; Schreiber, Nicole A et al. (2018) Assessment of the Validity of Nuclear-Localized Androgen Receptor Splice Variant 7 in Circulating Tumor Cells as a Predictive Biomarker for Castration-Resistant Prostate Cancer. JAMA Oncol 4:1179-1186
Bielski, Craig M; Zehir, Ahmet; Penson, Alexander V et al. (2018) Genome doubling shapes the evolution and prognosis of advanced cancers. Nat Genet 50:1189-1195
Luo, Jun; Attard, Gerhardt; Balk, Steven P et al. (2018) Role of Androgen Receptor Variants in Prostate Cancer: Report from the 2017 Mission Androgen Receptor Variants Meeting. Eur Urol 73:715-723
Settleman, Jeffrey; Sawyers, Charles L; Hunter, Tony (2018) Challenges in validating candidate therapeutic targets in cancer. Elife 7:
Miyazawa, Miki; Subbaramaiah, Kotha; Bhardwaj, Priya et al. (2018) Pioglitazone Inhibits Periprostatic White Adipose Tissue Inflammation in Obese Mice. Cancer Prev Res (Phila) 11:215-226
Graham, Laura; Banda, Kalyan; Torres, Alba et al. (2018) A phase II study of the dual mTOR inhibitor MLN0128 in patients with metastatic castration resistant prostate cancer. Invest New Drugs 36:458-467

Showing the most recent 10 out of 505 publications